Auris Medical Holding Ltd. (EARS)
Symbol Info
Listed Symbol EARS
Name Auris Medical Holding Ltd.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-14.64
Price Info
21 Day Moving Average $2.5043
21 Day EMA $2.390990
50 Day Moving Average $2.6726
50 Day EMA $2.633870
200 Day EMA $6.906290
200 Day Moving Average 4.808440
52 Week High $24.80
52 Week Low $1.85
52 Week Change $-88.823494
Alpha -0.065351
Beta 0.0122
Standard Deviation 0.241940
R2 0.000003
Periods 60
Share Information
10 Day Average Volume 189,832
20 Day Average Volume 133,311
30 Day Average Volume 170,216
50 Day Average Volume 125,768
Outstanding Shares 3,302,634
Float Shares 3,302,634
Percent Float 100.00%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 14
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months -
Institute Holdings Percent 2.300000
Institute Sold Previous 3 Months -
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned -
Price Change
7 Day Price Change $-0.2900001
7 Day Percent Change -13.24%
21 Day Price Change $-0.88
21 Day Percent Change -31.65%
30 Day Price Change $-1.18
30 Day Percent Change -38.31%
Month To Date Price Change $-0.85
Month To Date Percent -30.91%
90 Day Price Change $-0.75
90 Day Percent Change -28.30%
Quarter To Date $-0.85
Quarter To Date Percent -30.91%
180 Day Price Change $-4.356
180 Day Percent Change -69.63%
200 Day Price Change $-4.92
200 Day Percent Change -72.14%
Year To Date $-7.22
Year To Date Percent -79.17%
Profile
Description Auris Medical Holding Ltd is a clinical-stage biopharmaceutical company. The company develops novel products for the treatment of inner ear disorders. It has two projects in advanced clinical development Keyzilen for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. It is developing Keyzilen for the treatment of acute inner ear (peripheral) tinnitus following traumatic cochlear injury or otitis media (middle ear infection). Keyzilen contains Esketamine hydrochloride, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, formulated in a biocompatible and fully biodegradable gel. It is also developing AM-111 for the treatment of acute inner ear (sensorineural) hearing loss (ASNHL).
Details
Issue Type CS
Market Cap $6,275,005
Sec Type EQS
Auditor Deloitte AG
Total Shares Outstanding 3,302,634
CEO Thomas Meyer
Employees 11
Last Audit UE
Classification
CIK 0001601936
Industry Biotechnology
Sector Healthcare
NAICS
Info
Address Bahnhofstrasse 21
Zug, 6300
Website http://www.aurismedical.com
Facisimile
Telephone +41 417297194
Email Investors@aurismedical.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio 14.80
Enterprise Value $3,239,347
Price To Sales -
Price To Free Cash -0.8
PE High Last 5 Years -
Price To Book 1.0
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 1.0
Financial Strength
Total Debt To Equity -
Int Coverage -42.3
Current Ratio 3.5
Leverage Ratio 1.0
Quick Ratio 3.4
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -107.62
Return On Equity -376.84
Return On Capital -371.47
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
EARS
Auris Medi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.